Effectiveness of pneumococcal polysaccharide vaccine in older adults

被引:432
|
作者
Jackson, LA
Neuzil, KM
Yu, OC
Benson, P
Barlow, WE
Adams, AL
Hanson, CA
Mahoney, LD
Shay, DK
Thompson, WW
机构
[1] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Med, Seattle, WA USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[5] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA
[6] Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2003年 / 348卷 / 18期
关键词
D O I
10.1056/NEJMoa022678
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Streptococcus pneumoniae is the chief cause of pneumonia in older adults, but it remains unclear whether use of the pneumococcal polysaccharide vaccine alters the overall risk of community-acquired pneumonia. In a large population of older adults, we assessed the effectiveness of the pneumococcal vaccine. METHODS: In this retrospective cohort study, 47,365 Group Health Cooperative members 65 years of age or older were assessed over a three-year period. The primary outcomes were hospitalization because of community-acquired pneumonia (validated by chart review), pneumonia in patients who were not hospitalized (``outpatient pneumonia,'' determined from administrative data sources), and pneumococcal bacteremia. The association between pneumococcal vaccination and the risk of each outcome was evaluated by means of multivariate Cox proportional-hazards models, with adjustment for age, sex, nursing-home residence or nonresidence, smoking status, medical conditions, and receipt or nonreceipt of influenza vaccine. RESULTS: During the study period, 1428 cohort members were hospitalized with community-acquired pneumonia, 3061 were assigned a diagnosis of outpatient pneumonia, and 61 had pneumococcal bacteremia. Receipt of the pneumococcal vaccine was associated with a significant reduction in the risk of pneumococcal bacteremia (hazard ratio, 0.56; 95 percent confidence interval, 0.33 to 0.93) but a slightly increased risk of hospitalization for pneumonia (hazard ratio, 1.14; 95 percent confidence interval, 1.02 to 1.28). Pneumococcal vaccination did not alter the risk of outpatient pneumonia (hazard ratio, 1.04; 95 percent confidence interval, 0.96 to 1.13) or of any case of community-acquired pneumonia, whether or not it required hospitalization (hazard ratio, 1.07; 95 percent confidence interval, 0.99 to 1.14). CONCLUSIONS: These findings support the effectiveness of the pneumococcal polysaccharide vaccine for the prevention of bacteremia, but they suggest that alternative strategies are needed to prevent nonbacteremic pneumonia, which is a more common manifestation of pneumococcal infection in elderly persons.
引用
收藏
页码:1747 / 1755
页数:9
相关论文
共 50 条
  • [1] Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults
    Watson, L
    Wilson, BJ
    Waugh, N
    VACCINE, 2002, 20 (17-18) : 2166 - 2173
  • [2] The effectiveness of revaccination with pneumococcal polysaccharide vaccine for preventing pneumococcal disease in older adults in England: A population-based cohort study
    Doherty, Klara
    Bonnett, Laura
    Agbla, Schadrac C.
    Beveridge, Natalie E. R.
    Decraene, Valerie
    Fleming, Kate M.
    Hungerford, Daniel
    French, Neil
    VACCINE, 2024, 42 (22)
  • [3] Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea
    Kang, Dong-Won
    Kim, Chae-Rin
    Song, Joon Young
    Park, Sun-Kyeong
    VACCINE, 2024, 42 (04) : 871 - 878
  • [4] Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): In older adults
    Sanford M.
    Drugs, 2012, 72 (9) : 1243 - 1255
  • [5] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) In Older Adults
    Sanford, Mark
    DRUGS, 2012, 72 (09) : 1243 - 1255
  • [6] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in Navajo adults
    Benin, A
    O'Brien, K
    Watt, J
    Reid, R
    Zell, ER
    Katz, S
    Donaldson, C
    Parkinson, A
    Schuchat, A
    Santosham, M
    Whitney, CG
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1148 - 1148
  • [7] Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study
    Perniciaro, Stephanie
    van der Linden, Mark
    LANCET REGIONAL HEALTH-EUROPE, 2021, 7
  • [8] Pneumococcal polysaccharide vaccine in high risk adults
    Moberley, Sarah A.
    Torzillo, Paul
    BMJ-BRITISH MEDICAL JOURNAL, 2010, 340
  • [9] Erratum to Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed): In Older Adults
    M. Sanford
    Drugs, 2012, 72 : 2176 - 2176
  • [10] Pneumococcal vaccination of older adults Conjugate or polysaccharide?
    Hollingsworth, Rosalind
    Isturiz, Raul
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (01) : 45 - 46